Buy Femoston mini 2.5 mg + 0.5 mg film-coated tablets No. 28 in pharmacies
INN or group name:
Dydrogesterone + Estradiol.
Dosage form:
film-coated tablets.
Pharmacological properties*.
Estradiol. Estradiol hemihydrate, which is part of the drug Femoston® mini, when dissolved, turns into 17-β-estradiol, identical to endogenous human estradiol, which is the most active estrogen. Estradiol replenishes estrogen deficiency in the body in postmenopausal women and reduces the severity of menopausal symptoms.
Dydrogesterone. Dydrogesterone is a progestogen that is effective when taken orally and has activity similar to parenterally administered progesterone. Because estrogens promote endometrial proliferation, estrogen-only hormone replacement therapy (HRT) increases the risk of endometrial hyperplasia and cancer. The inclusion of dydrogesterone significantly reduces the risk of developing endometrial hyperplasia, increased under the influence of estrogen, in women with a preserved uterus. Clinical studies have shown that Femoston® mini provides relief from symptoms associated with estrogen deficiency and bleeding patterns.
Indications for use.
Hormone replacement therapy for disorders caused by estrogen deficiency in postmenopausal women (no earlier than 12 months after the last menstruation).
Contraindications.
Hypersensitivity to the components of the drug; diagnosed or suspected breast cancer; diagnosed or suspected estrogen-dependent malignancies (for example, endometrial cancer); diagnosed or suspected progestogen-dependent neoplasms (for example, meningioma); bleeding from the vagina of unknown etiology; untreated endometrial hyperplasia; thrombosis (arterial and venous) and thromboembolism currently or in history (including thrombosis, deep vein thrombosis; pulmonary embolism; myocardial infarction; ischemic or hemorrhagic cerebrovascular disorders); acute or chronic liver diseases currently or in history (before normalization of liver function tests), including malignant liver tumors; porphyria; multiple or pronounced factors of arterial or venous thrombosis associated with congenital or acquired predisposition, for example, protein C deficiency, protein S deficiency, antithrombin III deficiency, the presence of antibodies to phospholipids (anticardiolipin antibodies, lupus anticoagulant), angina pectoris, prolonged immobilization, severe forms obesity (body mass index more than 30 kg/m2), diseases of the cerebral vessels or coronary arteries, transient ischemic attacks, complicated lesions of the heart valve apparatus, atrial fibrillation; pregnancy and breastfeeding; galactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome; meningioma. Taking Femoston® mini should be discontinued if contraindications are identified and/or if the following conditions occur: jaundice and/or liver dysfunction; uncontrolled arterial hypertension; Migraine-like headaches that first appeared during the use of drugs for HRT, pregnancy.
Carefully.*
HRT is prescribed to women if any of the following conditions are currently diagnosed, have occurred previously and/or worsened during pregnancy or previous hormonal therapy: uterine leiomyoma, endometriosis; the presence of risk factors for the occurrence of estrogen-dependent tumors (for example, 1st degree relatives with breast cancer); arterial hypertension; benign liver tumors; diabetes mellitus, both in the presence of vascular complications and in their absence; cholelithiasis; migraine or severe headache; systemic lupus erythematosus; history of endometrial hyperplasia; epilepsy; bronchial asthma; otosclerosis. Precautionary measures must be observed in the following cases: in patients with chronic heart and renal failure; in patients with risk factors for the development of thrombosis and thromboembolism in a family history (thromboembolic complications in 1st degree relatives at a young age); in patients receiving anticoagulant therapy.
Use during pregnancy and breastfeeding*.
The drug is contraindicated during pregnancy and breastfeeding.
Directions for use and dosage.*
The drug is taken orally daily, continuously, 1 tablet per day (preferably at the same time of day), regardless of meals. Patients making a transition from another continuous sequential or cyclic regimen of the drug should complete the current cycle and then switch to Femoston® mini. Patients not receiving drugs for HRT or switching from a continuous regimen of combined drugs for HRT can start taking Femoston® mini on any day. Taking the combined drug for HRT Femoston® mini in women with natural menopause can begin no earlier than 12 months after the last menstruation. Women whose menopause is due to surgery can start taking the drug immediately (as prescribed by a doctor if symptoms are present).
Side effect*
In clinical studies, the most common symptoms reported in patients treated with the estradiol/dydrogesterone combination were headache, abdominal pain, breast tenderness/tenderness, and back pain.
A list of all side effects is presented in the instructions for medical use.
Overdose*.
Symptoms: nausea, vomiting, breast tension, dizziness, abdominal pain, drowsiness/weakness and withdrawal bleeding.
Treatment: Symptomatic.
Interaction with other drugs*.
No studies have been conducted to study interactions with other drugs. The metabolism of estrogens and progestogens can be enhanced when taken simultaneously with drugs that induce microsomal liver enzymes: anticonvulsants (phenobarbital, carbamazepine, phenytoin) and antimicrobial drugs (rifampicin, rifabutin, nevirapine, efavirenz); Ritonavir and nelfinavir, when used simultaneously with sex hormones, may enhance their metabolism; Preparations containing St. John's wort (Hypericum perforatum) may enhance the metabolism of estrogens and progestogens; Increased metabolism of estrogens and progestogens can be clinically manifested by a decrease in the effect of the drug and the appearance of bloody vaginal discharge.
Special instructions*.
The drug is prescribed only in the presence of symptoms that adversely affect the quality of life. Therapy should be continued until the benefits of taking the drug outweigh the risk of side effects. Experience with the drug in women over 65 years of age is limited. Information about the risks associated with HRT in cases of premature menopause is limited. Due to the lower absolute risk in younger women, their benefit/risk ratio may favor HRT compared with older women.
Impact on the ability to drive vehicles and machinery.
Care should be taken when operating vehicles and machinery, taking into account the risk of adverse reactions from the nervous system.
Storage conditions.
Store at a temperature not exceeding 25 °C. Keep out of the reach of children!
Vacation conditions.
Dispensed by prescription.
Indications for use
The use of Femoston is indicated for hormone replacement therapy to eliminate phenomena caused by estrogen deficiency in postmenopausal .
The medicine is prescribed no earlier than six months after the last menstrual bleeding.
Prophylactic use of the drug is advisable to prevent the development of osteoporosis after the onset of menopause . The drug is prescribed to women who have an increased risk of fractures and who are contraindicated in the use of other medications intended to prevent bone loss.
Side effects
The category of side effects that often occur in connection with the use of Femoston includes: pain (headaches, in the abdomen, in the pelvic area), nausea, migraine attacks, flatulence, leg cramps, increased sensitivity and/or tenderness of the mammary glands, metrorrhagia, the appearance of bloody vaginal bleeding after menopause, asthenia, decrease/increase in body weight.
With a frequency of 1/1000-1/100 during clinical studies, the following phenomena occurred:
- vaginal candidiasis;
- depression;
- an increase in the size of uterine fibroids ;
- change in libido ;
- increased nervousness;
- DVT, PE;
- dizziness;
- gallbladder disease ;
- backache;
- allergic reactions on the skin, accompanied by itching, hives , rashes;
- dysmenorrhea;
- ulcerative defects on the cervix;
- the appearance of cervical discharge;
- peripheral edema.
In rare cases (with a frequency of 1/10000-1/1000), drug therapy was accompanied by:
- intolerance to contact lenses;
- functional liver , which often manifest themselves in the form of asthenia , malaise, abdominal pain, jaundice ;
- increased curvature of the cornea;
- enlargement of the mammary glands;
- premenstrual tension syndrome.
In isolated cases, the drug can provoke the development of chorea , hemolytic anemia, stroke, myocardial infarction, vascular purpura, vomiting, erythema nodosum or multimorphic, melanopathy or chloasma (often persisting even after discontinuation of the drug), angioedema , hypersensitivity reactions, worsening of porphyrin disease .
In addition, in connection with treatment with estrogen-progestagen drugs, women sometimes develop neoplasms (benign, malignant or of unknown etiology), the size of progestogen-dependent tumors fibrocystic lesions of the mammary glands appear of triglycerides in the blood plasma and the concentration of thyroid hormones increase ; arterial hypertension , acute arterial , peripheral vascular disease, varicose , dyspepsia , pancreatitis (against the background of pre-existing hypertriglyceridermia), systemic lupus erythematosus , cystitis-like syndrome , urinary incontinence develop epilepsy worsens , signs of dementia .
Femoston tablets, instructions for use
Most often, Femoston is taken on days strictly determined by the attending physician, taking into account the characteristics of a particular menstrual cycle . In the absence of menstrual bleeding, the tablets should be taken on the expected days when they should begin. With amenorrhea observed throughout the year, taking the drug can be started at any time.
Instructions for use Femoston 1/5
The drug is intended for continuous use: tablets are taken p/os, one per day (optimally at the same time), without reference to meal times. The duration of one cycle is 4 full weeks (1 package No. 28 is designed for one cycle). There is no need to take a break between cycles.
To relieve the symptoms of menopause, the drug is started with the minimum effective dose. Treatment begins with the appointment of Femoston 1/5. Taking into account the time of onset of menopause, the severity of the accompanying symptoms and the effectiveness of therapy, adjustments can be made to the dosage regimen.
If it is necessary to switch from another drug containing estrogen and progestogen components for sequential (or cyclic) use, the patient should complete the full four-week course and only after that switch to treatment with Femoston 1/5 (reception can be started on any day). There is no break between cycles.
The regimen for using Femoston 1/5 Conti is similar to that described above.
Instructions for use Femoston 1/10
Femoston 1/10 tablets should be taken regardless of meal time. The estrogen contained in the drug is intended for continuous daily use during the first two weeks of the cycle.
The progestogen component is added in the last 14 days of each four-week course.
Treatment begins with taking white tablets according to the following scheme: 1 tablet 1 time per day (at the same time) during the first 2 weeks of the cycle. Next, following the instructions on the package, they begin to take gray tablets (also, one per day).
There is no need to take breaks between 28-day cycles.
Sequential combined HRT begins with the prescription of Femoston 1/10, and then, if necessary, the dose is adjusted taking into account the clinical results of therapy.
To switch from a similar drug, you should complete the full cycle of treatment and only then start taking Femoston 1/10 tablets. You can do this any day.
Instructions for use Femoston 2/10
The estrogen component of the drug should be taken continuously, the progestogen component is administered from the 15th day of the 28-day cycle.
This means that in the first 2 weeks of the cycle the patient should take 1 pink tablet per day, and starting from the 15th day, following the instructions on the drug packaging, switch to taking yellow tablets.
Usually the starting dose of estradiol is 1 mg, so sequential combined HRT begins with Femoston 1/10 and, if necessary, moves to a higher dose over time.
Switching from other drugs to Femoston 2/10 is carried out only after completing a full four-week cycle (on any day).
How to take Femoston correctly if you miss the next dose?
If a woman misses the next dose of the drug, the tablet should be taken as quickly as possible. If more than 12 hours have passed since the missed dose, then the course is continued by taking the next tablet from the package (you do not need to drink the missed one).
Taking a double dose to compensate for a missed dose is not advisable, since it is associated with an increased risk of breakthrough bleeding and the appearance of spotting vaginal discharge.
How should patients of different age groups take the drug?
There is no sufficient experience with the use of Femoston for the treatment of patients over 65 years of age.
There are no indications for prescribing the drug to children and adolescents.
